Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 1230Neoplasms 1040Carcinoma, Non-Small-Cell Lung 757Prostatic Neoplasms 697Colorectal Neoplasms 598Lung Neoplasms 578Pancreatic Neoplasms 403Leukemia, Myeloid, Acute 399Neoplasm Metastasis 391Ovarian Neoplasms 373Multiple Myeloma 373Stomach Neoplasms 319Carcinoma, Hepatocellular 304Melanoma 284Brain Neoplasms 281Recurrence 280Squamous Cell Carcinoma of Head and Neck 269Head and Neck Neoplasms 240Endometrial Neoplasms 236Glioblastoma 235Triple Negative Breast Neoplasms 230Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Lymphoma 226Uterine Cervical Neoplasms 225Sarcoma 202Hematologic Neoplasms 201Urinary Bladder Neoplasms 197Esophageal Neoplasms 192Carcinoma, Renal Cell 191Lymphoma, Non-Hodgkin 177

Interventions

fluorodopa F 18 1Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lewy Body Disease × 1 year × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡